- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: PTPN11.
Displaying page 1 of 1.
EudraCT Number: 2016-000647-14 | Sponsor Protocol Number: 15782601 | Start Date*: 2016-05-23 |
Sponsor Name:University Hospital Toulouse | ||
Full Title: Treatment with HMG-COA reductase inhibitor (simvastatin) of growth and bone abnormalities in children with Noonan syndrome : a phase III randomised, double-blind, placebo-controlled therapeutic trial | ||
Medical condition: Noonan syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003398-79 | Sponsor Protocol Number: MH21HEM | Start Date*: 2023-05-11 |
Sponsor Name:Princess Máxima Center for pediatric oncology | ||
Full Title: International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children Subprotocol D: Trametinib + Dexamethasone + C... | ||
Medical condition: Molecularly profiled r/r ALL/LBL whose tumor harbors an actionable event that can be targeted by the investigational agents. In this subprotocol, patients must present alterations in the RAS signal... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004370-10 | Sponsor Protocol Number: RUXO_LMMC-PRO_1401 | Start Date*: 2014-03-21 | |||||||||||
Sponsor Name:Grupo Español de Sindromes Mielodisplásicos (GESMD) | |||||||||||||
Full Title: A phase II study of ruxolitinib (INCB018424) to evaluate efficacy and safety in Patients with Proliferative Chronic Myelomonocytic Leukemia (CMML) | |||||||||||||
Medical condition: Proliferative Chronic Myelomonocytic Leukemia (CMML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003904-29 | Sponsor Protocol Number: RG_16-186 | Start Date*: 2017-07-12 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute L... | |||||||||||||
Medical condition: Relapsed/refractory acute lymphoblatic leukaemia with mutation in the RAS pathway | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) FR (Prematurely Ended) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002435-66 | Sponsor Protocol Number: FLAMSAClax | Start Date*: 2023-02-07 | |||||||||||
Sponsor Name:Heinrich-Heine-Universität Düsseldorf represented by the Coordinating Investigator | |||||||||||||
Full Title: Phase-I/II trial to assess the safety and efficacy of Venetoclax in addition to sequential conditioning with Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for allogeneic blood stem cell tra... | |||||||||||||
Medical condition: Patients with myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or secondary acute myeloid leukemia (sAML) before stem cell transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001982-26 | Sponsor Protocol Number: OZM-063 | Start Date*: 2018-04-26 | |||||||||||
Sponsor Name:The Hospital for Sick Children | |||||||||||||
Full Title: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma... | |||||||||||||
Medical condition: Unresectable or progressive low grade glioma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
